Intraocular Pharmacokinetics of Ranibizumab Following a Single Intravitreal Injection in Humans
- 20 July 2012
- journal article
- Published by Elsevier BV in American Journal of Ophthalmology
- Vol. 154 (4), 682-686.e2
- https://doi.org/10.1016/j.ajo.2012.03.047
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- Pharmacokinetics of Bevacizumab after Topical, Subconjunctival, and Intravitreal Administration in RabbitsInvestigative Opthalmology & Visual Science, 2009
- Mapping of the Neonatal Fc Receptor in the Rodent EyeInvestigative Ophthalmology & Visual Science, 2008
- Predicted biological activity of intravitreal VEGF TrapBritish Journal of Ophthalmology, 2008
- PREDICTED BIOLOGIC ACTIVITY OF INTRAVITREAL BEVACIZUMABRetina, 2007
- PHARMACOKINETICS AND RETINAL DISTRIBUTION OF RANIBIZUMAB, A HUMANIZED ANTIBODY FRAGMENT DIRECTED AGAINST VEGF-A, FOLLOWING INTRAVITREAL ADMINISTRATION IN RABBITSRetina, 2007
- FcRn: the neonatal Fc receptor comes of ageNature Reviews Immunology, 2007
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) after a Single Intravitreal AdministrationPublished by Association for Research in Vision and Ophthalmology (ARVO) ,2005
- Comparisons of the Intraocular Tissue Distribution, Pharmacokinetics, and Safety of 125I-Labeled Full-Length and Fab Antibodies in Rhesus Monkeys Following Intravitreal AdministrationToxicologic Pathology, 1999